We would love to hear your thoughts about our site and services, please take our survey here.
Has to be part of the government/treasury thinking? The invasion of Ukraine and a third world war , surely this is worse than the covid situation of 2020
If I had not maxed out my ISA this year more available I would add some more....
Died of or with? Makes a huge difference - the average age of death of those dying in the UK with/of/28 days after testing later apparently is 80 something - more are dying of flu than covid I read
https://www.telegraph.co.uk/news/2022/02/01/covid-really-deadly-flu-omicron-came-along/
and
https://www.telegraph.co.uk/news/2021/09/24/analysis-thousands-usual-dying-not-covid/
that did not age well - but maybe time to buy the dip
wish I'd added more in the summer any idea about why the rise - just general sentiment or is there a particular driver?
I go away for an hour and another rise -
Wish SAR would be infected with some HE1 excitement
logged on and what the hells been going on - not complaining but feck me this is looking good -
https://www.telegraph.co.uk/investing/funds/get-monthly-income-investments/
Another mention in the DT in an article about investing for monthly income...
HL is quoting 4.33 to buy at the moment, so the recent trades look like buys not sells
Unable to retrieve a live quote
Hargreave Lansdown could not place a deal just now -
I wonder if Syncona are shareholders
https://www.telegraph.co.uk/investing/shares/questor-trust-just-sold-holding-600m-entire-market-value-just/
Syncona, is an unusual beast: it invests in young life sciences companies with a view to holding them through the various stages of drug discovery, clinical trials, commercialisation and perhaps an eventual stock market listing.
I know we are listed but sounds like a fund that should be interested in Sareum
It obviously did not set the world alight as the share price has drifted - if it had been well received one would have expected some share price movement or buy ins
https://www.telegraph.co.uk/news/2021/11/18/astrazenecas-new-covid-antibody-treatment-effective-vaccines/
coronavirus drug derived from immune cells of Covid survivors gives better protection than vaccines after six months and could last for a year, trial results suggest.
AstraZeneca today announced that its antibody injection AZD7442 reduces the risk of symptomatic Covid by 83 per cent six months after a single dose.
In contrast, vaccines can wane substantially in the months following an injection, even after two doses, with the AstraZeneca vaccine falling to around 40 per cent effectiveness, and Pfizer about 60 per cent.
The company said the artificial antibodies appeared to last longer than the vaccine and a single injection could offer protection for a year, although have not yet been trialled in large populations.
The vaccines also initially showed higher protective effect in trials than real-world settings, although were hampered by the emergence of the Delta variant. In contrast, AZD7442 was trialled at a time when Delta was rampant.
Hugh Montgomery, professor of intensive care medicine at University College London, AZD7442 principal investigator, said: “These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives.
“Importantly, six months of protection was maintained despite the surge of the Delta variant among these high-risk participants who may not respond adequately to vaccination.”
A separate trial shows the drug also reduces the risk of severe Covid and death by 88 per cent when given within three days of symptom onset.
Potential breakthrough in treatment for elderly and vulnerable
The injection could be a breakthrough in treatment for elderly and immunocompromised people who cannot mount an adequate immune response against the virus, even after vaccination.
The research of both trials has been submitted for peer review, and is expected to be published in the coming weeks.
About one in 50 people does not make an adequate response to the vaccine, and the treatment could also be useful to helping protect at-risk groups, such as elderly people living in care homes.
Groups who could benefit include people with cancer who are being treated with chemotherapy, patients on dialysis, or those taking medication to suppress their immune systems following, such as people undergoing organ transplants, those with arthritis or people with multiple sclerosis.
The drug, which only needs to be administered in a single dose, is a combination of two antibodies which are derived from immune B-cells donated by convalescent patients who had recovered from the virus.
The antibodies bind to sites on the spike protein which the virus uses to enter cells.
AstraZenca said it had been designed to last for three times as long as conventional antibodies and a
real time data on electricity costs here
https://electricinsights.co.uk/#/homepage?_k=c5juk3
topped up £1500 @ 5.04p but showing as a sell
go big or go home - why not go for Hargreaves Lansdown
just topped up and my 7448 purchase is showing as a sell - still a punt at this price but if it heads north happy days....